IDEXX LABORATORIES INC /DE — Director's Dealing 2018

Aug 23, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2018-08-21

Reporting Person: Lane Michael (Corporate Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-21	Common Stock	M	2112	$62	Acquired	5519	Direct
2018-08-21	Common Stock	M	2226	$79.54	Acquired	7745	Direct
2018-08-21	Common Stock	M	1500	$67.85	Acquired	9245	Direct
2018-08-21	Common Stock	S	5838	$243.7776	Disposed	3407	Direct
2018-08-21	Common Stock	S	74	$243.75	Disposed	3333	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-21	Non-Qualified Stock Option (right-to-buy)	$62	M	2112	Disposed	2024-02-13	Common Stock (2112)	Direct
2018-08-21	Non-Qualified Stock Option (right-to-buy)	$79.54	M	2226	Disposed	2025-02-13	Common Stock (2226)	Direct
2018-08-21	Non-Qualified Stock Option (right-to-buy)	$67.85	M	1500	Disposed	2026-02-13	Common Stock (1500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	592	Indirect

Footnotes

F1: Includes 598 shares held in the reporting person's IRA account and 23 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2018.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $243.75 to a high of $244.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.

F4: Grant of option to buy 1,056 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F5: Grant of option to buy 1,181 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Grant of option to buy 10,749 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2017.

F7: Not applicable.